Case Report: Severe thrombocytopenia induced by adalimumab in rheumatoid arthritis: A case report and literature review

Case Report: Severe thrombocytopenia induced by adalimumab in rheumatoid arthritis: A case report and literature review

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. In recent decades, biological agents such as anti-tumor necrosis factor-α (TNF-α) drugs have been applied in the treatment of RA and it achieved great improvement. The treatment has its side e...

Full description

Bibliographic Details
Main Authors:	Tiantian Liao, Mengqing Li, Tian Yuan, Qifu Hong, Yu Zeng, Dan Yu, Qiong Yu, Limei Yu, Tao Pu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-10-01
Series:	Frontiers in Pharmacology
Subjects:	rheumatoid arthritis adalimumab thrombocytopenia complication biologic therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1041884/full

Similar Items

ADALIMUMAB DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING SUSTAINED REMISSION
by: N. V. Demidova, et al.
Published: (2018-07-01)

Lethality of patients with rheumatoid arthritis depending on adalimumab administration: imitation modeling
by: D V Goryachev, et al.
Published: (2009-10-01)

Treatment with either leflunomide or adalimumab reduces anaemia in patients with rheumatoid arthritis
by: Ione C.P. Pereira, et al.
Published: (2018-06-01)

Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis
by: G. Andrisani, et al.
Published: (2013-05-01)

Adalimumab impact on fatigue measured by FACIT-F: a study of rheumatoid arthritis patients in Saudi Arabia
by: Janoudi N, et al.
Published: (2017-10-01)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
by: Sanjiv Kapoor, et al.
Published: (2019-06-01)

RESULTS OF RETROSPECTIVE OBSERVATIONAL STUDY OF ADALIMUMAB SAFETY AND EFFICACY IN PATIENTS WITH JUVENILE ARTHRITIS AND UVEITIS
by: Е.I. Alexeeva, et al.
Published: (2011-01-01)

Nephritis, cerebritis, and myositis after adalimumab therapy in a patient with rheumatoid arthritis: a case report
by: Omran NE, et al.
Published: (2018-04-01)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
by: Roy M. Fleischmann, et al.
Published: (2018-08-01)

Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis
by: Christina A. Spivey, et al.
Published: (2019-11-01)

Granulomatosis with polyangiitis: Rheumatoid arthritis overlap syndrome: A case report
by: Ashraf E. Sileem, et al.
Published: (2017-01-01)

Case report: Safety and efficacy of adalimumab in treating difficult-to-treat rheumatoid arthritis in a human immunodeficiency virus-positive patient, one year follow-up
by: Jing-Wen Chen, et al.
Published: (2022-08-01)

First expirience of adalimumab administration in Russia: preliminary results of an open 24 week study
by: E L Luchichina, et al.
Published: (2008-10-01)

EFFICACY OF ADALIMUMAB IN EARLY RHEUMATOID ARTHRITIS IN RELATION TO ITS SERUM LEVEL AND THE PRESENCE OF ANTI-DRUG ANTIBODY
by: A. S. Avdeeva, et al.
Published: (2014-12-01)

Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
by: Chen HH, et al.
Published: (2016-02-01)

The efficiency and safety of adalimumab treatment in patients with active rheumatoid arthritis unresponsive to standard therapy: Russian national study results
by: D E Karateev, et al.
Published: (2012-08-01)

Novel DNA methylome biomarkers associated with adalimumab response in rheumatoid arthritis patients
by: Ishtu Hageman, et al.
Published: (2023-12-01)

Cerebral Toxoplasmosis as an Uncommon Complication of Biologic Therapy for Rheumatoid Arthritis: Case Report and Review of the Literature
by: Gonçalo Borges de Almeida, et al.
Published: (2022-08-01)

Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab
by: Seong-Kyu Kim, et al.
Published: (2023-04-01)

A rare case of suicidal ideation related to Adalimumab use
by: Jafri F, et al.
Published: (2018-08-01)

Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study
by: Areej S. Albahdal, et al.
Published: (2024-02-01)

Anti-glomerular basement membrane-antibody disease in a patient treated with adalimumab for rheumatoid arthritis
by: V Heron, et al.
Published: (2020-01-01)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
by: Roy M. Fleischmann, et al.
Published: (2021-09-01)

Invasive Cryptococcosis and Adalimumab Treatment
by: Juan P. Horcajada, et al.
Published: (2007-06-01)

Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
by: Claudiu Costinel Popescu, et al.
Published: (2022-12-01)

Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis
by: Jing-Wen Chen, et al.
Published: (2022-12-01)

Aseptic Abscess Syndrome in Rheumatoid Arthritis Patient
by: Agnieszka Owczarczyk-Saczonek, et al.
Published: (2022-09-01)

Continuous effectiveness and safety after a hospital‐wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients
by: Rianne Brouwer, et al.
Published: (2022-12-01)

A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis
by: Ahmadreza Jamshidi, et al.
Published: (2017-07-01)

Effects of Etanercept and Adalimumab on Serum Levels of Cartilage Remodeling Markers in Women with Rheumatoid Arthritis
by: Anna Szeremeta, et al.
Published: (2023-08-01)

Restoration of Default Blood Monocyte-Derived Macrophage Polarization With Adalimumab But Not Etanercept in Rheumatoid Arthritis
by: Audrey Paoletti, et al.
Published: (2022-02-01)

CHANGES OF CYTOKINE LEVELS DURING THERAPY WITH METHOTREXATE AND ADALIMUMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS (REMARCA STUDY)
by: A. S. Avdeeva, et al.
Published: (2014-06-01)

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis
by: Maryam Shayesteh Alam, MD, FRCPC, FAAD, et al.
Published: (2020-03-01)

Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real‐world finding
by: Zhe Yu, et al.
Published: (2024-02-01)

THE FIRST EXPERIENCE IN USING ADALIMUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: CLINICAL AND MRICOMPARISONS OF THE RESULTS OF THERAPY
by: A G Bochkova, et al.
Published: (2010-02-01)

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
by: Vibeke Strand, et al.
Published: (2018-06-01)

A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate
by: Prasad Apsangikar, et al.
Published: (2018-01-01)

COVID-19—A Trigger Factor for Severe Immune-Mediated Thrombocytopenia in Active Rheumatoid Arthritis
by: Anca Bobircă, et al.
Published: (2022-01-01)

Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis
by: Andrea Becciolini, et al.
Published: (2022-02-01)

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry
by: Favalli EG, et al.
Published: (2018-05-01)